4.7 Article

Discovery of new [1,2,4] Triazolo[1,5-a]Pyrimidine derivatives that Kill gastric cancer cells via the mitochondria pathway

Journal

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 203, Issue -, Pages -

Publisher

ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2020.112630

Keywords

1,2,4]triazolo[1,5-a]pyrimidines; Autophagy; Apoptosis; Mitochondrial pathway; Gastric cancer

Funding

  1. National Natural Science Foundation of China [81773562, 81973177, 81703326]
  2. China Postdoctoral Science Foundation [2018M630840, 2019M662551, 2019T120641]

Ask authors/readers for more resources

Mitochondria are known as powerhouse of cells and play the role of a bridge in redox balance, cell apoptosis, and autophagy. ROS accumulation can cause mitochondria damage, while the injured mitochondria will further enhance ROS levels reciprocally. Herein, we synthesized a novel series of [1,2,4] triazolo[1,5-a]pyrimidine-based compounds 4a-4v and tested their anti-proliferation efficacy against gastric cancer cell line MGC-803. Among them, compounds 4o and 4p inhibited gastric cancer cells at micromolar level. Compound 4o caused G2/M arrest and induced mitochondria-dependent apoptosis in MGC-803 and SGC-7901. However, inhibiting apoptosis pathway cannot prevent the inhibitory activity of compound 4o against gastric cancer cell. To our surprising, ROS level was increased by compound 4o and elevation of ROS could be rescued by NAC. In accordance with that, NAC absolutely prevented the anti-proliferation efficacy of compound 4o. We further found that autophagy inhibitor CQ rather than 3-MA partially reversed inhibitory activity of compound 4o in MGC-803 cells. Taken together, compound 4o exhibited its anti-proliferative activity via increasing ROS level and inducing autophagy, thus leading to apoptosis of gastric cancer cells. Therefore, compound 4o may support further development of lead compounds for gastric cancer therapy via mitochondria pathway. (C) 2020 Elsevier Masson SAS. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Pharmacology & Pharmacy

Repurposing antidepressants for anticancer drug discovery

Yihui Song, Xiaoke Yang, Bin Yu

Summary: Drug repurposing is an attractive strategy for finding new indications for existing drugs. Three approved antidepressants have shown potential in clinical trials for cancer treatment. By conducting further medicinal chemistry research, several TCP-based inhibitors of the histone lysine specific demethylase 1 enzyme have been discovered, showing promise for cancer treatment. Repurposing antidepressants could be a promising strategy for cancer treatment.

DRUG DISCOVERY TODAY (2022)

Review Chemistry, Medicinal

Annual review of lysine-specific demethylase 1 (LSD1/KDM1A) inhibitors in 2021

Yihui Song, Huiqing Zhang, Xiaoke Yang, Yuting Shi, Bin Yu

Summary: Lysine-specific demethylase 1 (LSD1/KDM1A) has emerged as a promising epigenetic target for disease treatment. This review provides an update on LSD1 inhibitors, including natural products, synthetic compounds, and cyclic peptides reported in 2021. The design strategies, structure-activity relationships, binding model analysis, and modes of action are discussed. Highlights include the repurposing of FDA-approved drugs as reversible LSD1 inhibitors, the identification of clinical candidates for neuro-developmental disorders, and the enhanced anti-cancer effects of dual inhibitors targeting both LSD1 and HDAC6 or tubulin.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)

Article Chemistry, Medicinal

Structure-based design, synthesis and biological evaluation of aminopyrazines as highly potent, selective, and cellularly active allosteric SHP2 inhibitors

Kai Tang, Min Zhao, Ya-Hong Wu, Qiong Wu, Shu Wang, Yu Dong, Bin Yu, Yihui Song, Hong-Min Liu

Summary: The study presents a highly potent, selective, and cellularly active allosteric SHP2 inhibitor TK-453, which modulates the phosphorylation of cell signaling pathways by inhibiting the phosphatase activity of SHP2.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)

Article Chemistry, Medicinal

Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and PROTAC-based degraders for cancer therapy

Kai Tang, Bo Wang, Bin Yu, Hong-Min Liu

Summary: Indoleamine 2,3-dioxygenase 1 (IDO1) is an important immunosuppressive enzyme in cancer therapy. Multiple IDO1 inhibitors have entered clinical trials, and PROTAC-based degraders also show promise for cancer treatment.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)

Article Biochemistry & Molecular Biology

Structure-based drug design of potential inhibitors of FBXW8, the substrate recognition component of Cullin-RING ligase 7

Yingying Zhang, Liuqing Cui, Wangji Chen, Benny Danilo Belviso, Bin Yu, Yunpeng Shen

Summary: This study developed an integrated approach to screen FBXW8 inhibitors and identified three compounds with potential as therapeutic candidates for CRL7-related cancers.

MOLECULAR DIVERSITY (2023)

Article Chemistry, Medicinal

Structure-guided design of novel HEPT analogs with enhanced potency and safety: From Isopropyl-HEPTs to Cyclopropyl-HEPTs

Ruo-Lan Zhou, Zhiran Ju, Christophe Pannecouque, Erik De Clercq, Shuai Wang, Fen-Er Chen

Summary: In this study, novel cyclopropyl-substituted HEPT analogs were developed to improve their potency and safety as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Compound 9h exhibited significantly increased inhibitory activity against wild-type HIV-1 (EC50=0.017μM) compared to the lead compound 2. It also showed reduced cytotoxicity with a higher selectivity index (SI>2328) and promising pharmacokinetics profiles.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Chemistry, Medicinal

Structural and Functional Landscape of FAD-Dependent Histone Lysine Demethylases for New Drug Discovery

Yihui Song, Shu Wang, Bin Yu

Summary: Small molecules targeting the FAD-dependent LSD family have shown promise as therapeutic candidates for various diseases. Nine clinical candidates are currently being investigated for their ability to treat cancers and neurodegenerative diseases. In addition, noncatalytic functions of LSDs are being explored as a new strategy for disease treatment. This Perspective provides a comprehensive analysis of the LSD family, including its structure, function, and different types of inhibitors, with the aim of identifying new druggable targets for LSD inhibitors. The strategies for targeting LSD's demethylase-independent functions are also briefly discussed.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Chemistry, Medicinal

Structure-Based Design of the Indole-Substituted Triazolopyrimidines as New EED-H3K27me3 Inhibitors for the Treatment of Lymphoma

Guanjun Dong, Jiahui Zuo, Junlin Yu, Jiale Xu, Ge Gao, Guo-Bo Li, Wen Zhao, Bin Yu

Summary: This study presents a new triazolopyrimidine-based EED inhibitor that disrupts embryonic ectoderm development and inhibits tumor growth with excellent pharmacokinetic profiles. It has the potential for lymphoma treatment.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Biochemistry & Molecular Biology

Discovery of novel benzohydroxamate-based histone deacetylase 6 (HDAC6) inhibitors with the ability to potentiate anti-PD-L1 immunotherapy in melanoma

Xiaopeng Peng, Ziwen Yu, Goverdhan Surineni, Bulian Deng, Meizhu Zhang, Chuan Li, Zhiqiang Sun, Wanyi Pan, Yao Liu, Shenglan Liu, Bin Yu, Jianjun Chen

Summary: In this study, a series of novel HDAC6 inhibitors containing polycyclic aromatic rings were discovered and evaluated for their pharmacological activities. Compound 10c showed high inhibitory activity against HDAC6 and selectivity over HDAC3. It also exhibited decent antiproliferative activity against cancer cell lines and demonstrated potential as an anti-cancer agent. Furthermore, the combination of 10c with a PD-L1 inhibitor showed promising results in reducing tumor burden and enhancing the anti-tumor immune response.

JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2023)

Article Chemistry, Medicinal

Fragment Hopping-Based Design of Novel Biphenyl-DAPY Derivatives as Potent Non-Nucleoside Reverse Transcriptase Inhibitors Featuring Significantly Improved Anti-Resistance Efficacy

Ya-Li Sang, Christophe Pannecouque, Erik De Clercq, Shuai Wang, Fen-Er Chen

Summary: A series of novel biphenyl-DAPY derivatives were developed using the fragment-hopping strategy to enhance the anti-resistance efficacy of a non-nucleoside reverse transcriptase inhibitor (NNRTI). Most of the compounds exhibited improved anti-HIV-1 potency, with compound 8r showing exceptional potency against wild-type HIV-1 and mutant strains. The new DAPY analogue had lower cytotoxicity, higher selectivity index, and favorable pharmacokinetic properties, making it a potential candidate for HIV treatment.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Chemistry, Analytical

Development of a robust HTRF assay with USP7 full length protein expressed in E. coli prokaryotic system for the identification of USP7 inhibitors

Yihui Song, Shu Wang, Min Zhao, Bin Yu

Summary: USP7, a deubiquitinating enzyme, is a promising therapeutic target. Through the development of a reliable fluorescence high-throughput screening method and the identification of potential ligandable pockets in the full length of USP7, we have enriched the toolbox for the discovery of potent and selective USP7 inhibitors.

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2023)

Article Chemistry, Multidisciplinary

A Nearly 20-Year Journey to Success of Azvudine for Antiviral Therapy

Bin Yu, Junbiao Chang

Summary: Azvudine, a modified nucleoside, has been approved for the treatment of HIV-1 and COVID-19. It acts by inhibiting viral replication and has shown effectiveness in clinical trials. It has received conditional authorization in China and Russia.

CHINESE JOURNAL OF CHEMISTRY (2023)

Editorial Material Chemistry, Medicinal

Targeted covalent inhibitors for novel therapeutics

Jingya Zhang, Wenshuo Gao, Yixia Wang, Junbiao Chang, Bin Yu

FUTURE MEDICINAL CHEMISTRY (2023)

Article Toxicology

Influences of lysine-specific demethylase 1 inhibitors on NO synthase-Kruppel-like factor pathways in human endothelial cells in vitro and zebrafish (Danio rerio) larvae in vivo

Jialin Yuan, Ruiman Que, Weichao Zhao, Fengmei Song, Yi Cao, Bin Yu

Summary: In this study, the effects of two LSD1 inhibitors, ORY-1001 and 199, were compared on HUVECs in vitro and on zebrafish larvae in vivo. The results showed that both ORY-1001 and 199 had negligible effects on cell viability but significantly reduced the release of inflammatory cytokines and increased NO production. In zebrafish larvae, ORY-1001 treatment also affected blood flow and gene expression related to inflammation and vasculature function.

JOURNAL OF APPLIED TOXICOLOGY (2023)

Review Biochemistry & Molecular Biology

Targeting epigenetic regulators to overcome drug resistance in cancers

Nan Wang, Ting Ma, Bin Yu

Summary: Drug resistance is a major cause of cancer recurrence and poor prognosis. Epigenetic regulation, which involves heritable changes in gene expression, is independent of changes in nucleotide sequences. Three common mechanisms of epigenetic regulation, DNA methylation, histone modification, and non-coding RNA regulation, have been extensively studied. Aberrant epigenetic regulation has been shown to contribute to tumor resistance, making targeting epigenetic regulators an effective strategy to reverse drug resistance. This review summarizes the roles of epigenetic regulation in tumor resistance and discusses the functions and regulatory mechanisms of histone demethylases, as well as therapeutic strategies for overcoming drug resistance.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2023)

Article Chemistry, Medicinal

Highly potent dual-targeting angiotensin-converting enzyme 2 (ACE2) and Neuropilin-1 (NRP1) peptides: A promising broad-spectrum therapeutic strategy against SARS-CoV-2 infection

Shuang Mei, Su Jiang, Yuting Wang, Han Jing, Peng Yang, Miao-Miao Niu, Jindong Li, Kai Yuan, Yan Zhang

Summary: This study identifies a dual-targeting peptide, AP-1, that effectively inhibits variants of concern (VOCs) of SARS-CoV-2 without impairing host cell viability. The findings suggest that AP-1 could be a promising broad-spectrum agent for treating emerging VOCs of SARS-CoV-2.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2024)

Article Chemistry, Medicinal

Discovery of proteolysis-targeting chimera targeting undruggable proteins using a covalent ligand screening approach

Hyeonjun Lee, Ju Yeon Lee, Hyunsoo Jang, Hye Young Cho, Minhee Kang, Sang Hyun Bae, Suin Kim, Eunji Kim, Jaebong Jang, Jin Young Kim, Young Ho Jeon

Summary: By using liquid chromatography-tandem mass spectrometry and nuclear magnetic resonance experiments, we identified new chemical moieties that bind to the target sites of the protein of interest, allowing for reversible binding and protein degradation. This method has the potential to expand the application of PROTAC technology.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2024)

Article Chemistry, Medicinal

A pro-death autophagy-based nanoplatform for enhancing antitumour efficacy with improved immune responses

Yingying Li, Xiyou Du, Xinru Kong, Yuelin Fang, Zhijing He, Dongzhu Liu, Hang Wu, Jianbo Ji, Xiaoye Yang, Lei Ye, Guangxi Zhai

Summary: This study proposes a novel nanoplatform based on the autophagy cascade to overcome the obstacles in chemo-immunotherapy. The platform combines chemotherapy and starvation therapy to initiate pro-death autophagy and enhance antigen presentation, while also remodeling the immunosuppressive tumor microenvironment. Furthermore, the study discovers a new therapeutic direction for the respiration inhibitor 3-bromopyruvic acid (3BP) in cancer treatment. Overall, this study offers an opportunity to improve antitumor efficacy and boost immune responses.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2024)

Article Chemistry, Medicinal

A novel scaffold long-acting selective estrogen receptor antagonist and degrader with superior preclinical profile against ER plus breast cancer

Bingsi Wang, Mingxu Ma, Yusen Dai, Pengfei Yu, Liang Ye, Wenyan Wang, Chunjie Sha, Huijie Yang, Yingjie Yang, Yunjing Zhu, Lin Dong, Shujuan Wei, Linlin Wang, Jingwei Tian, Hongbo Wang

Summary: Breast cancer is a common malignant tumor in women, and drug resistance remains a clinical challenge. In this study, a novel compound, G-5b, was developed with potent antagonistic and degradation activities comparable to the current drug fulvestrant. G-5b also showed improved stability and solubility. Mechanistically, G-5b engages the proteasome pathway to degrade ER, inhibiting the ER signaling pathway and inducing apoptosis and cell cycle arrest. In animal models, G-5b exhibited superior pharmacokinetics and pharmacodynamics properties. Overall, G-5b is a promising long-acting SERD worthy of further investigation and optimization.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2024)

Article Chemistry, Medicinal

HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents

Karoline B. Waitman, Larissa C. de Almeida, Marina C. Primi, Jorge A. E. G. Carlos, Claudia Ruiz, Thales Kronenberger, Stefan Laufer, Marcia Ines Goettert, Antti Poso, Sandra V. Vassiliades, Vinicius A. M. de Souza, Monica F. Z. J. Toledo, Neuza M. A. Hassimotto, Michael D. Cameron, Thomas D. Bannister, Leticia Costa-Lotufo, Joa o A. Machado-Neto, Mauricio T. Tavares, Roberto Parise-Filho

Summary: A series of hybrid inhibitors combining pharmacophores of known kinase inhibitors and benzohydroxamate HDAC inhibitors were synthesized and evaluated for their anticancer activity and pharmacokinetic properties. Compounds 4d-f exhibited promising cytotoxicity against hematological cells and moderate activity against solid tumor models. Compound 4d showed potent inhibition of multiple kinase targets and had stable interactions with HDAC and members of the JAK family. These compounds showed selective cytotoxicity with minimal effects on non-tumorigenic cells and favorable pharmacokinetic profiles.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2024)

Article Chemistry, Medicinal

Unexpected rearrangement of ivermectin in the synthesis of new derivatives with trypanocidal and antiplasmodial activities

Michal Sulik, Diana Fontinha, Dietmar Steverding, Szymon Sobczak, Michal Antoszczak, Miguel Prudencio, Adam Huczynski

Summary: This study describes the synthesis of the first-in-class ivermectin derivatives obtained through derivatization of the C13 position, along with the unexpected rearrangement of the macrolide ring. These derivatives show potential for antiparasitic activity and are important for the development of new antiparasitic agents.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2024)

Article Chemistry, Medicinal

Novel ligustilide derivatives target quorum sensing system LasR/LasB and relieve inflammatory response against Pseudomonas aeruginosa infection

Jun Liu, Qiu-Xian Chen, Wen-Fu Wu, Dong Wang, Si -Yu Zhao, Jia-Hao Li, Yi-Qun Chang, Shao-Gao Zeng, Jia-Yi Hu, Yu-Jie Li, Jia-Xin Du, Shu-Meng Jiao, Hai-Chuan Xiao, Qiang Zhang, Jun Xu, Jian-Fu Zhao, Hai -Bo Zhou, Yong-Heng Wang, Jian Zou, Ping-Hua Sun

Summary: A new anti-infective drug strategy has been discovered to attenuate virulence and modulate inflammation caused by drug-resistant Pseudomonas aeruginosa infections. Compound 5f inhibits biofilm formation, macrophage migration, and inflammatory response induced by P. aeruginosa, showing potential as a novel candidate against drug-resistant infections.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2024)

Article Chemistry, Medicinal

Design and synthesis of pterostilbene derivatives bearing triazole moiety that might treat DSS-induced colitis in mice through modulation of NF-KB/ MAPK signaling pathways

Liuzeng Chen, Ke Wang, Lingyun Wang, Wei Wang, Lifan Wang, Jia Li, Xiaohan Liu, Mengya Wang, Banfeng Ruan

Summary: In this study, a series of novel anti-inflammatory compounds were designed and synthesized based on the natural product pterostilbene skeleton. Among them, compound 8 showed the highest activity and exhibited its effects through inhibition of pro-inflammatory cytokines by blocking the NF-KB/MAPK signaling pathway. Compound 8 also demonstrated a good relieving effect on acute colitis in mice and showed good safety in acute toxicity experiments.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2024)

Article Chemistry, Medicinal

Discovery of 4-(N-dithiobenzyl piperazine)-1,8-naphthalimide as a potent multi-target antitumor agent with good efficacy, limited toxicity, and low resistance

Si-Min Liang, Gui-Bin Liang, Hui-Ling Wang, Hong Jiang, Xian-Li Ma, Jian-Hua Wei, Ri-Zhen Huang, Ye Zhang

Summary: A series of novel multi-target antitumor agents were designed, synthesized, and evaluated. Some compounds exhibited significant antitumor activity and one compound showed excellent efficacy, limited toxicity, and low resistance. Further mechanism studies revealed that the compound exerted antitumor effects through multiple pathways.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2024)